Literature DB >> 21755461

Regulation of epithelial to mesenchymal transition: CK2β on stage.

Alexandre Deshiere1, Eve Duchemin-Pelletier, Elodie Spreux, Delphine Ciais, Christelle Forcet, Claude Cochet, Odile Filhol.   

Abstract

Protein kinase CK2 participates in the regulation of fundamental cellular processes. Among these processes, cell polarity and cell morphology are controlled by this enzyme probably through the phosphorylation of key proteins. To further study the involvement of CK2 in these processes, we showed that in epithelial cells, the regulatory CK2β subunit was required for LKB1-dependent polarization and cell adhesion. Moreover, CK2β silencing in MCF10A mammary epithelial cells triggered changes in their morphology correlated with the acquisition of mesenchymal phenotype, which were reminiscent to TGFβ-induced epithelial-to-mesenchymal-transition (EMT). TGFβ has emerged as a major inducer of EMT both in vitro and in vivo. We found that among the TGFβ isoforms, TGFβ2 expression was strongly induced in CK2β-knockdown cells. However, the EMT phenotype induced in response to CK2β silencing was not abolished by blocking the TGFβ signaling pathway at TGFβ receptor level, suggesting that alternative pathways might be involved. Given the importance of CK2 in tumorigenesis, a dysregulation of CK2β expression might contribute to EMT induction during cancer progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755461     DOI: 10.1007/s11010-011-0942-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  22 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

Review 4.  TGF-beta signaling in breast cancer.

Authors:  Miriam B Buck; Cornelius Knabbe
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

5.  Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics.

Authors:  Jonine D Figueroa; Kathleen C Flanders; Montserrat Garcia-Closas; William F Anderson; Xiaohong R Yang; Rayna K Matsuno; Máire A Duggan; Ruth M Pfeiffer; Akira Ooshima; Robert Cornelison; Gretchen L Gierach; Louise A Brinton; Jolanta Lissowska; Beata Peplonska; Lalage M Wakefield; Mark E Sherman
Journal:  Breast Cancer Res Treat       Date:  2009-11-24       Impact factor: 4.872

6.  Protein kinase CK2 and cell polarity.

Authors:  Alexandre Deshière; Nathalie Theis-Febvre; Véronique Martel; Claude Cochet; Odile Filhol
Journal:  Mol Cell Biochem       Date:  2008-06-28       Impact factor: 3.396

Review 7.  Protein kinase CK2 in health and disease: Cellular functions of protein kinase CK2: a dynamic affair.

Authors:  O Filhol; C Cochet
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

Review 8.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

Review 9.  LKB1 tumor suppressor protein: PARtaker in cell polarity.

Authors:  Annette F Baas; Linda Smit; Hans Clevers
Journal:  Trends Cell Biol       Date:  2004-06       Impact factor: 20.808

Review 10.  TGF-beta-induced epithelial to mesenchymal transition.

Authors:  Jian Xu; Samy Lamouille; Rik Derynck
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

View more
  7 in total

Review 1.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

2.  A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases.

Authors:  Nicolas Carels; Tatiana Tilli; Jack A Tuszynski
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

3.  The size-speed-force relationship governs migratory cell response to tumorigenic factors.

Authors:  Aldo Leal-Egaña; Gaelle Letort; Jean-Louis Martiel; Andreas Christ; Timothée Vignaud; Caroline Roelants; Odile Filhol; Manuel Théry
Journal:  Mol Biol Cell       Date:  2017-04-20       Impact factor: 4.138

4.  Protein kinase CK2 activation is required for transforming growth factor β-induced epithelial-mesenchymal transition.

Authors:  Seongrak Kim; Sunyoung Ham; Kyungmi Yang; Kunhong Kim
Journal:  Mol Oncol       Date:  2018-09-21       Impact factor: 6.603

5.  CK2β Is a Gatekeeper of Focal Adhesions Regulating Cell Spreading.

Authors:  Odile Filhol; Anne-Marie Hesse; Anne-Pascale Bouin; Corinne Albigès-Rizo; Florian Jeanneret; Christophe Battail; Delphine Pflieger; Claude Cochet
Journal:  Front Mol Biosci       Date:  2022-06-29

6.  Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.

Authors:  Tatiana M Tilli; Nicolas Carels; Jack A Tuszynski; Manijeh Pasdar
Journal:  Oncotarget       Date:  2016-09-27

7.  Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells.

Authors:  Eve Duchemin-Pelletier; Megghane Baulard; Elodie Spreux; Magali Prioux; Mithila Burute; Baharia Mograbi; Laurent Guyon; Manuel Théry; Claude Cochet; Odile Filhol
Journal:  Cancers (Basel)       Date:  2017-08-31       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.